Fleury S.A. - Asset Resilience Ratio
Fleury S.A. (FLRY3) has an Asset Resilience Ratio of 16.06% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Fleury S.A.'s equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Fleury S.A.'s Asset Resilience Ratio has changed over time. See how leveraged is Fleury S.A.'s balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Fleury S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Fleury S.A. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$0.00 | 0% |
| Short-term Investments | R$2.14 Billion | 16.06% |
| Total Liquid Assets | R$2.14 Billion | 16.06% |
Asset Resilience Insights
- Good Liquidity Position: Fleury S.A. maintains a healthy 16.06% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Fleury S.A. Industry Peers by Asset Resilience Ratio
Compare Fleury S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
Annual Asset Resilience Ratio for Fleury S.A. (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Fleury S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.19% | R$2.14 Billion ≈ $420.03 Million |
R$13.22 Billion ≈ $2.59 Billion |
-1.57pp |
| 2024-12-31 | 17.76% | R$2.32 Billion ≈ $455.22 Million |
R$13.06 Billion ≈ $2.56 Billion |
+9.97pp |
| 2023-12-31 | 7.79% | R$902.21 Million ≈ $177.03 Million |
R$11.58 Billion ≈ $2.27 Billion |
-8.79pp |
| 2022-12-31 | 16.58% | R$1.29 Billion ≈ $253.56 Million |
R$7.79 Billion ≈ $1.53 Billion |
+3.92pp |
| 2021-12-31 | 12.67% | R$769.39 Million ≈ $150.97 Million |
R$6.07 Billion ≈ $1.19 Billion |
-5.78pp |
| 2020-12-31 | 18.45% | R$1.02 Billion ≈ $199.61 Million |
R$5.51 Billion ≈ $1.08 Billion |
+2.83pp |
| 2019-12-31 | 15.62% | R$795.89 Million ≈ $156.17 Million |
R$5.10 Billion ≈ $1.00 Billion |
-4.96pp |
| 2018-12-31 | 20.57% | R$804.49 Million ≈ $157.85 Million |
R$3.91 Billion ≈ $767.30 Million |
+1.56pp |
| 2017-12-31 | 19.01% | R$670.57 Million ≈ $131.58 Million |
R$3.53 Billion ≈ $692.13 Million |
+5.59pp |
| 2016-12-31 | 13.42% | R$403.47 Million ≈ $79.17 Million |
R$3.01 Billion ≈ $589.80 Million |
+13.28pp |
| 2015-12-31 | 0.15% | R$4.70 Million ≈ $922.81K |
R$3.20 Billion ≈ $628.73 Million |
+1.13pp |
| 2014-12-31 | -0.98% | R$-31.46 Million ≈ $-6.17 Million |
R$3.21 Billion ≈ $629.81 Million |
-0.58pp |
| 2013-12-31 | -0.40% | R$-12.97 Million ≈ $-2.54 Million |
R$3.21 Billion ≈ $630.09 Million |
-0.01pp |
| 2012-12-31 | -0.40% | R$-10.86 Million ≈ $-2.13 Million |
R$2.74 Billion ≈ $537.28 Million |
-0.41pp |
| 2011-12-31 | 0.02% | R$434.00K ≈ $85.16K |
R$2.83 Billion ≈ $555.63 Million |
+0.01pp |
| 2010-12-31 | 0.00% | R$19.00K ≈ $3.73K |
R$1.33 Billion ≈ $260.61 Million |
+1.36pp |
| 2009-12-31 | -1.36% | R$-17.07 Million ≈ $-3.35 Million |
R$1.26 Billion ≈ $246.48 Million |
+2.93pp |
| 2008-12-31 | -4.29% | R$-26.44 Million ≈ $-5.19 Million |
R$616.76 Million ≈ $121.02 Million |
-2.36pp |
| 2007-12-31 | -1.93% | R$-9.75 Million ≈ $-1.91 Million |
R$505.94 Million ≈ $99.27 Million |
+5.58pp |
| 2006-12-31 | -7.51% | R$-24.48 Million ≈ $-4.80 Million |
R$326.11 Million ≈ $63.99 Million |
-- |
About Fleury S.A.
Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and cli… Read more